Ventana Medical Systems, Inc. CONFIRM CD15 760-2504

Description
Antibodies against CD15 normally react in a strong cell surface membrane staining pattern with granulocytes and granulocyte precursors, monocytes, a subset of tissue macrophages, and activated T lymphocytes. CONFIRM anti-CD15 (MMA) also reacts against the Reed-Sternberg cells of Hodgkin's disease and, because it recognizes a carbohydrate antigen, is also expressed by a variety of carcinoma types but is negative in malignant mesotheliomas. Antibodies against CD15 are used diagnostically to (1) support a diagnosis of acute myeloid leukemia, (2) help support a diagnosis of Hodgkin'sdisease, and (3) help separate poorly differentiated adenocarcinomas from malignant mesothelioma.
Datasheet
Description
Antibodies against CD15 normally react in a strong cell surface membrane staining pattern with granulocytes and granulocyte precursors, monocytes, a subset of tissue macrophages, and activated T lymphocytes. CONFIRM anti-CD15 (MMA) also reacts against the Reed-Sternberg cells of Hodgkin's disease and, because it recognizes a carbohydrate antigen, is also expressed by a variety of carcinoma types but is negative in malignant mesotheliomas. Antibodies against CD15 are used diagnostically to (1) support a diagnosis of acute myeloid leukemia, (2) help support a diagnosis of Hodgkin'sdisease, and (3) help separate poorly differentiated adenocarcinomas from malignant mesothelioma.
Datasheet

Suppliers

Company
Product
Description
Supplier Links
CONFIRM CD15 - 760-2504 - Ventana Medical Systems, Inc.
Tucson, AZ, USA
CONFIRM CD15
760-2504
CONFIRM CD15 760-2504
Antibodies against CD15 normally react in a strong cell surface membrane staining pattern with granulocytes and granulocyte precursors, monocytes, a subset of tissue macrophages, and activated T lymphocytes. CONFIRM anti-CD15 (MMA) also reacts against the Reed-Sternberg cells of Hodgkin's disease and, because it recognizes a carbohydrate antigen, is also expressed by a variety of carcinoma types but is negative in malignant mesotheliomas. Antibodies against CD15 are used diagnostically to (1) support a diagnosis of acute myeloid leukemia, (2) help support a diagnosis of Hodgkin'sdisease, and (3) help separate poorly differentiated adenocarcinomas from malignant mesothelioma.

Antibodies against CD15 normally react in a strong cell surface membrane staining pattern with granulocytes and granulocyte precursors, monocytes, a subset of tissue macrophages, and activated T lymphocytes. CONFIRM anti-CD15 (MMA) also reacts against the Reed-Sternberg cells of Hodgkin's disease and, because it recognizes a carbohydrate antigen, is also expressed by a variety of carcinoma types but is negative in malignant mesotheliomas. Antibodies against CD15 are used diagnostically to (1) support a diagnosis of acute myeloid leukemia, (2) help support a diagnosis of Hodgkin'sdisease, and (3) help separate poorly differentiated adenocarcinomas from malignant mesothelioma.

Datasheet

Technical Specifications

  Ventana Medical Systems, Inc.
Product Category Organic Chemicals
Product Number 760-2504
Product Name CONFIRM CD15
Unlock Full Specs
to access all available technical data

Similar Products

Intermediates and Ingredients for Pharmaceuticals and Agrochemical Compounds -  - AGC Chemicals Americas, Inc.
Specs
Chemical Family All Halogenated
Chemical Name Trifluoroacetic Acid, Trifluoroacetic Anhydride, Ethyl Trifluoroacetate, Sodium Trifluoroacetate, 2,3,4-Trifluoro aniline, Trifluoroacetamide, & More
CAS Number 76-05-1, 407-25-0, 383-63-1, 2923-18-4, 3862-73-5, 354-38-1, 148043-73-6, 30071-93-3, 677-69-0, 122665-97-8, 118612-00-3, 136040-19-2, and More
View Details
DMI 1,3 Dimethyl-2-Imidazolidinone -  - Mitsui Chemicals America, Inc.
Mitsui Chemicals America, Inc.
Specs
Trigger Solvent
Chemical Name DMI 1,3 Dimethyl-2-Imidazolidinone
State of Matter Liquid / Solution
View Details